| abstract |
The present invention is directed to methods for treating, delaying, slowing the progression of and / or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ACE inhibitors or one or more ARBs or one or more PPAR-gamma agonists; and to methods for treating, delaying, slowing the progression of and / or preventing fatty liver disorders (for example, NASH or NAFLD), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin. |